By Christy Santhosh April 27 (Reuters) - Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax ...

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in ...

U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the global market.

Eli Lilly and Co. LLY is phasing out select insulin products across parts of Europe for commercial reasons, with regulators emphasizing that the move is not linked to safety or quality concerns. The ...

Kelonia is developing a next-gen blood cancer treatment that’ll reprogram T-cells to help patients’ immune systems fight ...

In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to ...

A doctor discusses common issues and questions around Foundayo, the oral obesity pill approved by the FDA this week.

It's no secret that Eli Lilly's (NYSE: LLY) strong performance in recent years is due in large part to its clinical and commercial progress with tirzepatide, a medicine approved for diabetes and ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) has been the winner in the massive GLP-1 drug category, the class of medications that have proven extremely effective in lowering blood sugar levels and ...